Search

everythinglearnresearchcommunity

for

Search:↓

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

The conversation discusses the effects of finasteride on hair loss and its potential neurological and sexual side effects. Users share personal experiences, with some reporting positive outcomes and others expressing concerns about cognitive function.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Whether topical caffeine can be as effective for hair growth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A 30-year-old with Norwood 3V hair loss uses finasteride 1.25 mg every other day and Minoxidil (Regaine 5%) twice daily, experiencing no side effects with the current regimen. The front hairline remains unchanged, but the crown appears better in certain lighting.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

Cold shock therapy may promote hair growth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

OP had a doctor appointment, was advised to try B vitamins and change shampoo for hair loss, and may consider Finasteride if no improvement. Users suggest seeing a dermatologist directly, as vitamins likely won't help much with AGA.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

Microneedling can cause a sneezing reflex due to tingling in the nose. Users report this reaction, especially in the temple region.

Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."

A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.

A user shared a blog post by "swissTemples" claiming to have reversed hair loss using a combination of treatments including suppressing PGD2 and increasing PGE2. The user noted that "swissTemples" has been banned from forums, possibly due to conflicts of interest.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

A user found that antihistamines stop their hair loss and related symptoms, but they experience side effects like sedation and chest pain. They are seeking alternative solutions or topical antihistamines to avoid systemic side effects.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.